杆菌的CA抑制可以抑制Helicobacter pylori
Bianca Laura Bernardoni1, Concettina La Motta1, Simone Carradori2
1Department of Pharmacy, University of Pisa, Pisa, Italy.
The Enzymes
|September 2, 2024
概括
杆菌感染是由于耐药性而造成的全球健康风险. 向Hp碳酸无水酶 (HpαCA和HpβCA) 为开发新的抗菌剂提供了一个有前途的战略.
科学领域:
- 微生物学与传染病的研究
- 生物化学和酶学 生物化学和酶学
- 药物发现和药理学
背景情况:
- 杆菌 (Hp) 感染是全球主要的健康问题,与胃癌和胃潰瘍等严重疾病有关.
- 抗微生物耐药性的增加需要针对HP的新型治疗策略.
- 碳酸无水酶 (HpαCA和HpβCA) 对于病原体的生存至关重要,并且代表着有前途的药物标.
研究的目的:
- 探索Hp碳酸无水酶 (HpαCA和HpβCA) 作为对抗H. pylori感染的治疗点的潜力.
- 调查这些酶在H. pylori病变发生中的药用性和重要作用.
- 通过表征这些酶及其抑制剂,为开发新的抗菌剂奠定基础.
主要方法:
- 对HpαCA和HpβCA异酶的分离和表征.
- 精制的碳酸酶酶的动态分析.
- 对Hp碳酸无水酶的抑制剂系列的选.
主要成果:
- 这项研究成功地隔离和表征了HpαCA和HpβCA.
- 分析了这两种异酶的动力性质.
- 针对这些酶的抑制剂系列进行了初步调查.
结论:
- 碳酸无水化Hp被证实是高度可用药的标,在H. pylori的生存中起着至关重要的作用.
- 对HpαCA和HpβCA的表征为针对H. pylori的合理药物设计提供了基础.
- 开发这些酶的抑制剂为新的抗H. pylori疗法提供了显著的潜力,以解决耐药性的问题.
相关概念视频
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
335
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
335
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
100
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
100
01:22Pathophysiology of Peptic Ulcer Disease: Injurious Factors
545
Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
545
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
358
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
358
01:26Peptic Ulcer Disease IV: Management
78
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
78
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
410
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
410